MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
Galectin Therapeutics ROCE Ratio 2011-2026 | GALT
Annual ROCE Ratio Galectin Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15.7 | 40.49 | 61.44 | 113.08 | -3379.51 | -96.96 | -29.44 | -197.19 | -1361.86 | -178.78 | -80.16 | -55.16 | -147.13 | -124.94 | -236.73 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 113.08 | -3379.51 | -377.14 |
Quarterly ROCE Ratio Galectin Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23.79 | 30.07 | 39.64 | 36.34 | 53.76 | 61.57 | 65.14 | 57.77 | 91.53 | 107.86 | 147.85 | 216.28 | 106.74 | -36.56 | -146.8 | -201.03 | -227.4 | -144.23 | -118.16 | -69.48 | -76.01 | -56.16 | -35.89 | -18.8 | -70.59 | -115.85 | -181.61 | -205.16 | 627.67 | 1512.29 | 2436.62 | 2617.74 | 2573.65 | 1696.74 | 791.3 | -164.03 | -196.73 | -185.35 | -157.42 | -85.34 | -101.75 | -85.45 | -75.56 | -55.18 | -294.55 | -517.51 | -673.56 | -627.95 | -876.54 | -885.76 | -942.79 | -645.24 | -549.57 | -205.31 | 164.45 | 331.15 | 95.67 | 140.75 | 94.73 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2617.74 | -942.79 | 86.3 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K |  USA |
 |
BioNTech SE
BNTX
|
-4.81 | $ 97.54 | -5.71 % | $ 27.2 B | Germany |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
Burford Capital Limited
BUR
|
14.24 | $ 5.2 | 5.69 % | $ 820 M |  Britain |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M | Britain |
 |
AlloVir
ALVR
|
-58.56 | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B | France |
 |
Cerus Corporation
CERS
|
-13.52 | $ 2.72 | 33.99 % | $ 518 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
31.5 | $ 21.95 | -2.23 % | $ 3.64 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-368.0 | - | - | $ 269 M | USA |
 |
Applied Molecular Transport
AMTI
|
-209.11 | - | - | $ 10.1 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
11.12 | - | - | $ 96.9 B | Britain |
 |
Atreca
BCEL
|
-34.9 | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
-69.03 | - | -7.31 % | $ 87 M | USA |
 |
Calithera Biosciences
CALA
|
-1377.15 | - | -10.95 % | $ 876 K | USA |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-34.79 | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
-45.41 | - | - | $ 3.74 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Cardiff Oncology
CRDF
|
-107.87 | $ 1.71 | -1.16 % | $ 114 M | USA |
 |
Caladrius Biosciences
CLBS
|
-75.78 | - | -16.75 % | $ 25.8 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-88.5 | - | - | $ 231 M | USA |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M |  Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
163.63 | - | -2.5 % | $ 5.88 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-60.12 | - | - | $ 2.18 B | USA |
 |
AIkido Pharma
AIKI
|
-80.33 | - | 1.93 % | $ 17.4 M | USA |
 |
Editas Medicine
EDIT
|
-586.37 | $ 2.9 | -3.33 % | $ 257 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
-0.69 | - | - | $ 2.02 B | USA |
 |
Edesa Biotech
EDSA
|
-354.07 | $ 17.59 | -3.75 % | $ 56.2 M | USA |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-116.14 | - | - | $ 28.6 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-146.69 | $ 2.93 | -8.15 % | $ 4.82 M | Israel |
 |
Eiger BioPharmaceuticals
EIGR
|
496.51 | - | -9.21 % | $ 2.55 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
322.88 | - | -5.68 % | $ 8.28 M | USA |
 |
CureVac N.V.
CVAC
|
-51.5 | - | - | $ 867 M | Germany |
 |
Ampio Pharmaceuticals
AMPE
|
-75.24 | - | -11.43 % | $ 502 K | USA |
 |
Applied Therapeutics
APLT
|
394.73 | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-163.42 | - | -39.0 % | $ 4.57 M | USA |
 |
Evogene Ltd.
EVGN
|
-39.87 | $ 0.81 | 3.33 % | $ 27.9 M | Israel |
 |
Aravive
ARAV
|
-664.7 | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
123.77 | - | 17.91 % | $ 11.1 M | USA |